1) Those of us with Vascepa prescriptions, now on-label after 12/19, will continue to receive Vascepa label capsules.
2) In above situation, we might receive Vazkepa prescriptions. With both marks registered in U.S., it seems easier to retain Vascepa label for broader label indications.
ANother strategy on using a reset button but since Vazkepa is still EPA whats to prevent the substitution from occurring as they now are ? Yes its not indicated yes its patent infringement but insurance companies will still substitute - we will still need legal actions to prevent ...
Similar to my Vastor idea but a bit easier to make the substitution